Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 897–904 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BeyondSpring Inc. Plinabulin with pegfilgrastim Multiple Myeloma Phase 2 Intravenous Oncology
BeyondSpring Inc. KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01) 2L/3L Non-small cell lung cancer (NSCLC) Phase 2 Data Released Intravenous Oncology
BeyondSpring Inc. Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP) 1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Phase 2 Enrollment Initiation Intravenous Oncology
Bicara Therapeutics Inc. Ficerafusp Alfa (BCA101) with Pembrolizumab - (FORTIFI-HN01) R/M Head and Neck Squamous Cell Carcinoma Phase 2/3 Ongoing Intravenous Oncology
Bicycle Therapeutics plc THR-149 (KALAHARI) Diabetic Macular Edema Phase 2 Trial Completed Intravitreal Opthalmic
Bio-Path Holdings Inc. INOpulse Inhaled Nitric Oxide COVID-19 Phase 3 Trial Discontinued Inhalation COVID-19
Bio-Path Holdings Inc. INOpulse Inhaled Nitric Oxide COVID-19 Phase 3 Trial Discontinued Inhalation COVID-19
BioAtla Inc. Mecbotamab Vedotin (BA3011) Solid Tumors Phase 2 Trial Completed Intravenous Oncology
1…111112113114115…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.